Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12550455 | 0.78 | SMN1; SMN2 (0.47) | SMN1; SMN2SLC6A3CYP2D6SLC6A4LMNA | |
| SCHEMBL12860871 | 0.75 | SLC6A3 (0.41) | SLC6A3CYP2D6SLC6A4POLBTDP1 | |
| SCHEMBL27534985 | 0.73 | TACR1 (0.55) | CYP2D6POLBCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL23875683 | 0.70 | LTB4R (0.52) | POLBGAA | |
| SCHEMBL30530341 | 0.70 | AOC3 (0.52) | LMNAGAA | |
| Benzoic Acid Dimethylcarbamoylmethyl Ester SCHEMBL9651513 | 0.69 | NPC1 (0.56) | SMN1; SMN2SLC6A3SLC6A2TDP1LMNA | |
| SCHEMBL15793307 | 0.69 | GAA (0.41) | SMN1; SMN2CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL4055535 | 0.68 | ALDH1A1 (0.49) | SMN1; SMN2SLC6A3CYP2D6TDP1LMNA | |
| SCHEMBL3632818 | 0.68 | SMN1; SMN2 (0.86) | SMN1; SMN2POLB | |
| SCHEMBL8897325 | 0.68 | GABBR2 (0.44) | SMN1; SMN2CYP2D6CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180177748-A1 | COMBINATION MEDICATION FOR NEURO-DEGENERATIVE DISEASES | FECHTER CARY ERWIN (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180177748-A1 | COMBINATION MEDICATION FOR NEURO-DEGENERATIVE DISEASES | SLC18A2, SLC6A4, SLC6A2 | SMN1; SMN2 77/4885SLC6A3 5/4885CYP2D6 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.